Effects of low-dose clonidine on cardiovascular and autonomic variables in adolescents with chronic fatigue

A randomized controlled trial

Even Fagermoen, Dag Sulheim, Anette Winger, Anders M. Andersen, Johannes Gjerstad, Kristin Godang, Peter Rowe, J. Philip Saul, Eva Skovlund, Vegard Bruun Wyller

Research output: Contribution to journalArticle

Abstract

Background: Chronic Fatigue Syndrome (CFS) is a common and disabling condition in adolescence with few treatment options. A central feature of CFS is orthostatic intolerance and abnormal autonomic cardiovascular control characterized by sympathetic predominance. We hypothesized that symptoms as well as the underlying pathophysiology might improve by treatment with the alpha2A-adrenoceptor agonist clonidine. Methods: A total of 176 adolescent CFS patients (12-18 years) were assessed for eligibility at a single referral center recruiting nation-wide. Patients were randomized 1:1 by a computer system and started treatment with clonidine capsules (25 μg or 50 μg twice daily, respectively, for body weight below/above 35 kg) or placebo capsules for 9 weeks. Double-blinding was provided. Data were collected from March 2010 until October 2012 as part of The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial (NorCAPITAL). Effect of clonidine intervention was assessed by general linear models in intention-to-treat analyses, including baseline values as covariates in the model. Results: A total of 120 patients (clonidine group n = 60, placebo group n = 60) were enrolled and started treatment. There were 14 drop-outs (5 in the clonidine group, 9 in the placebo group) during the intervention period. At 8 weeks, the clonidine group had lower plasma norepinephrine (difference = 205 pmol/L, p = 0.05) and urine norepinephrine/creatinine ratio (difference = 3.9 nmol/mmol, p = 0.002). During supine rest, the clonidine group had higher heart rate variability in the low-frequency range (LF-HRV, absolute units) (ratio = 1.4, p = 0.007) as well as higher standard deviation of all RR-intervals (SDNN) (difference = 12.0 ms, p = 0.05); during 20° head-up tilt there were no statistical differences in any cardiovascular variable. Symptoms of orthostatic intolerance did not change during the intervention period. Conclusions: Low-dose clonidine reduces catecholamine levels in adolescent CFS, but the effects on autonomic cardiovascular control are sparse. Clonidine does not improve symptoms of orthostatic intolerance. Trial registration: Clinical Trials ID: NCT01040429 , date of registration 12/28/2009.

Original languageEnglish (US)
Article number117
JournalBMC Pediatrics
Volume15
Issue number1
DOIs
StatePublished - Sep 10 2015

Fingerprint

Clonidine
Fatigue
Randomized Controlled Trials
Chronic Fatigue Syndrome
Orthostatic Intolerance
Placebos
Capsules
Norepinephrine
Intention to Treat Analysis
Computer Systems
Therapeutics
Adrenergic Receptors
Catecholamines
Linear Models
Creatinine
Referral and Consultation
Heart Rate
Head
Body Weight
Clinical Trials

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Effects of low-dose clonidine on cardiovascular and autonomic variables in adolescents with chronic fatigue : A randomized controlled trial. / Fagermoen, Even; Sulheim, Dag; Winger, Anette; Andersen, Anders M.; Gjerstad, Johannes; Godang, Kristin; Rowe, Peter; Saul, J. Philip; Skovlund, Eva; Wyller, Vegard Bruun.

In: BMC Pediatrics, Vol. 15, No. 1, 117, 10.09.2015.

Research output: Contribution to journalArticle

Fagermoen, E, Sulheim, D, Winger, A, Andersen, AM, Gjerstad, J, Godang, K, Rowe, P, Saul, JP, Skovlund, E & Wyller, VB 2015, 'Effects of low-dose clonidine on cardiovascular and autonomic variables in adolescents with chronic fatigue: A randomized controlled trial', BMC Pediatrics, vol. 15, no. 1, 117. https://doi.org/10.1186/s12887-015-0428-2
Fagermoen, Even ; Sulheim, Dag ; Winger, Anette ; Andersen, Anders M. ; Gjerstad, Johannes ; Godang, Kristin ; Rowe, Peter ; Saul, J. Philip ; Skovlund, Eva ; Wyller, Vegard Bruun. / Effects of low-dose clonidine on cardiovascular and autonomic variables in adolescents with chronic fatigue : A randomized controlled trial. In: BMC Pediatrics. 2015 ; Vol. 15, No. 1.
@article{5dcbcc29bd7f4d04820fb14b08417dc0,
title = "Effects of low-dose clonidine on cardiovascular and autonomic variables in adolescents with chronic fatigue: A randomized controlled trial",
abstract = "Background: Chronic Fatigue Syndrome (CFS) is a common and disabling condition in adolescence with few treatment options. A central feature of CFS is orthostatic intolerance and abnormal autonomic cardiovascular control characterized by sympathetic predominance. We hypothesized that symptoms as well as the underlying pathophysiology might improve by treatment with the alpha2A-adrenoceptor agonist clonidine. Methods: A total of 176 adolescent CFS patients (12-18 years) were assessed for eligibility at a single referral center recruiting nation-wide. Patients were randomized 1:1 by a computer system and started treatment with clonidine capsules (25 μg or 50 μg twice daily, respectively, for body weight below/above 35 kg) or placebo capsules for 9 weeks. Double-blinding was provided. Data were collected from March 2010 until October 2012 as part of The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial (NorCAPITAL). Effect of clonidine intervention was assessed by general linear models in intention-to-treat analyses, including baseline values as covariates in the model. Results: A total of 120 patients (clonidine group n = 60, placebo group n = 60) were enrolled and started treatment. There were 14 drop-outs (5 in the clonidine group, 9 in the placebo group) during the intervention period. At 8 weeks, the clonidine group had lower plasma norepinephrine (difference = 205 pmol/L, p = 0.05) and urine norepinephrine/creatinine ratio (difference = 3.9 nmol/mmol, p = 0.002). During supine rest, the clonidine group had higher heart rate variability in the low-frequency range (LF-HRV, absolute units) (ratio = 1.4, p = 0.007) as well as higher standard deviation of all RR-intervals (SDNN) (difference = 12.0 ms, p = 0.05); during 20° head-up tilt there were no statistical differences in any cardiovascular variable. Symptoms of orthostatic intolerance did not change during the intervention period. Conclusions: Low-dose clonidine reduces catecholamine levels in adolescent CFS, but the effects on autonomic cardiovascular control are sparse. Clonidine does not improve symptoms of orthostatic intolerance. Trial registration: Clinical Trials ID: NCT01040429 , date of registration 12/28/2009.",
author = "Even Fagermoen and Dag Sulheim and Anette Winger and Andersen, {Anders M.} and Johannes Gjerstad and Kristin Godang and Peter Rowe and Saul, {J. Philip} and Eva Skovlund and Wyller, {Vegard Bruun}",
year = "2015",
month = "9",
day = "10",
doi = "10.1186/s12887-015-0428-2",
language = "English (US)",
volume = "15",
journal = "BMC Pediatrics",
issn = "1471-2431",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Effects of low-dose clonidine on cardiovascular and autonomic variables in adolescents with chronic fatigue

T2 - A randomized controlled trial

AU - Fagermoen, Even

AU - Sulheim, Dag

AU - Winger, Anette

AU - Andersen, Anders M.

AU - Gjerstad, Johannes

AU - Godang, Kristin

AU - Rowe, Peter

AU - Saul, J. Philip

AU - Skovlund, Eva

AU - Wyller, Vegard Bruun

PY - 2015/9/10

Y1 - 2015/9/10

N2 - Background: Chronic Fatigue Syndrome (CFS) is a common and disabling condition in adolescence with few treatment options. A central feature of CFS is orthostatic intolerance and abnormal autonomic cardiovascular control characterized by sympathetic predominance. We hypothesized that symptoms as well as the underlying pathophysiology might improve by treatment with the alpha2A-adrenoceptor agonist clonidine. Methods: A total of 176 adolescent CFS patients (12-18 years) were assessed for eligibility at a single referral center recruiting nation-wide. Patients were randomized 1:1 by a computer system and started treatment with clonidine capsules (25 μg or 50 μg twice daily, respectively, for body weight below/above 35 kg) or placebo capsules for 9 weeks. Double-blinding was provided. Data were collected from March 2010 until October 2012 as part of The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial (NorCAPITAL). Effect of clonidine intervention was assessed by general linear models in intention-to-treat analyses, including baseline values as covariates in the model. Results: A total of 120 patients (clonidine group n = 60, placebo group n = 60) were enrolled and started treatment. There were 14 drop-outs (5 in the clonidine group, 9 in the placebo group) during the intervention period. At 8 weeks, the clonidine group had lower plasma norepinephrine (difference = 205 pmol/L, p = 0.05) and urine norepinephrine/creatinine ratio (difference = 3.9 nmol/mmol, p = 0.002). During supine rest, the clonidine group had higher heart rate variability in the low-frequency range (LF-HRV, absolute units) (ratio = 1.4, p = 0.007) as well as higher standard deviation of all RR-intervals (SDNN) (difference = 12.0 ms, p = 0.05); during 20° head-up tilt there were no statistical differences in any cardiovascular variable. Symptoms of orthostatic intolerance did not change during the intervention period. Conclusions: Low-dose clonidine reduces catecholamine levels in adolescent CFS, but the effects on autonomic cardiovascular control are sparse. Clonidine does not improve symptoms of orthostatic intolerance. Trial registration: Clinical Trials ID: NCT01040429 , date of registration 12/28/2009.

AB - Background: Chronic Fatigue Syndrome (CFS) is a common and disabling condition in adolescence with few treatment options. A central feature of CFS is orthostatic intolerance and abnormal autonomic cardiovascular control characterized by sympathetic predominance. We hypothesized that symptoms as well as the underlying pathophysiology might improve by treatment with the alpha2A-adrenoceptor agonist clonidine. Methods: A total of 176 adolescent CFS patients (12-18 years) were assessed for eligibility at a single referral center recruiting nation-wide. Patients were randomized 1:1 by a computer system and started treatment with clonidine capsules (25 μg or 50 μg twice daily, respectively, for body weight below/above 35 kg) or placebo capsules for 9 weeks. Double-blinding was provided. Data were collected from March 2010 until October 2012 as part of The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial (NorCAPITAL). Effect of clonidine intervention was assessed by general linear models in intention-to-treat analyses, including baseline values as covariates in the model. Results: A total of 120 patients (clonidine group n = 60, placebo group n = 60) were enrolled and started treatment. There were 14 drop-outs (5 in the clonidine group, 9 in the placebo group) during the intervention period. At 8 weeks, the clonidine group had lower plasma norepinephrine (difference = 205 pmol/L, p = 0.05) and urine norepinephrine/creatinine ratio (difference = 3.9 nmol/mmol, p = 0.002). During supine rest, the clonidine group had higher heart rate variability in the low-frequency range (LF-HRV, absolute units) (ratio = 1.4, p = 0.007) as well as higher standard deviation of all RR-intervals (SDNN) (difference = 12.0 ms, p = 0.05); during 20° head-up tilt there were no statistical differences in any cardiovascular variable. Symptoms of orthostatic intolerance did not change during the intervention period. Conclusions: Low-dose clonidine reduces catecholamine levels in adolescent CFS, but the effects on autonomic cardiovascular control are sparse. Clonidine does not improve symptoms of orthostatic intolerance. Trial registration: Clinical Trials ID: NCT01040429 , date of registration 12/28/2009.

UR - http://www.scopus.com/inward/record.url?scp=84941215060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941215060&partnerID=8YFLogxK

U2 - 10.1186/s12887-015-0428-2

DO - 10.1186/s12887-015-0428-2

M3 - Article

VL - 15

JO - BMC Pediatrics

JF - BMC Pediatrics

SN - 1471-2431

IS - 1

M1 - 117

ER -